Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Azitra, Inc. (AZTR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, which are central to understanding this clinical stage biopharmaceutical issuer focused on precision dermatology. Through its Forms 8-K, S-1, DEF 14A and related documents, Azitra outlines the status of its live biotherapeutic and engineered protein programs, capital structure, and stock exchange compliance.
Filings such as Form 8-K detail material events, including notices from NYSE American regarding non-compliance with minimum stockholders’ equity requirements and subsequent acceptance of Azitra’s plan to regain compliance by April 1, 2027. Other 8-K reports describe private placement transactions involving common stock, pre-funded warrants, and common stock purchase warrants, as well as placement agency agreements and registration rights agreements tied to these financings. Additional 8-Ks furnish quarterly financial results and discuss reverse stock split actions implemented through amendments to the company’s certificate of incorporation.
Azitra’s Form S-1 registration statements provide further insight into its equity line of credit with Alumni Capital LP, the potential issuance of ELOC shares and warrants, and the resale registration of securities issued in private transactions. These documents explain how the company may raise capital over time and the number and types of securities that may be issued. The DEF 14A definitive proxy statement for a Special Meeting of Stockholders describes proposals to approve share issuances under NYSE American rules, including shares underlying warrants issued pursuant to a securities purchase agreement.
On this page, Stock Titan pairs Azitra’s real-time EDGAR filings feed with AI-powered summaries that help explain the significance of key documents. Users can quickly understand stock issuance proposals, listing standard issues, reverse stock splits, and financing structures without reading every page of each filing. Access to forms related to insider or major holder transactions, when filed, complements this view by showing how ownership and capital structure evolve as Azitra advances its ATR-12, ATR-04, and ATR-01 programs.
Azitra, Inc. has called a virtual special stockholder meeting on February 6, 2026 to vote on issuing more than 19.99% of its outstanding common stock under NYSE American rules. The key item is approval of common shares issuable upon exercise of warrants held by Alumni Capital LP under a November 24, 2025 securities purchase agreement. Azitra has already raised about $1.5 million in gross proceeds from this private placement and could receive an additional $1.5 million in gross proceeds if the Alumni Capital warrants are exercised for cash in full, plus about $75,000 if placement agent warrants are fully exercised.
The company states that existing cash and short-term investments, including recent financings, will not fund operating and capital needs for the next twelve months. If it cannot raise additional capital in the very near term, Azitra warns it may need to delay or cut development efforts, reduce marketing, or potentially cease operations and seek protection under the United States Bankruptcy Code. Approval of the proposal would also eliminate an exchange cap limiting issuances to 19.99% and would increase dilution and potential share price volatility for current stockholders. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.
Azitra, Inc. is asking stockholders to approve the issuance of more than 19.99% of its outstanding common stock, through shares underlying warrants issued to Alumni Capital LP under a November 24, 2025 securities purchase agreement. This approval is required under NYSE American rules to lift a 19.99% cap tied to the private placement.
The company has already closed the offering, selling 535,759 shares and issuing pre-funded and common stock purchase warrants at an offering price of $0.32, raising approximately $1.5 million in gross proceeds. If stockholders approve Proposal 1 and Alumni Capital exercises all its warrants for cash, Azitra would receive an additional $1.5 million, increasing total gross proceeds from the transaction to about $3.0 million. The Board warns that without this approval and additional capital, existing cash will not fund operations for the next twelve months and the company may need to sharply cut programs or potentially seek bankruptcy protection. A second proposal would allow adjournment of the special meeting to solicit more proxies if needed.
Azitra, Inc. reported an insider equity award for a senior executive and director. On 12/19/2025, the reporting person was granted stock options to acquire 23,724 shares of common stock at an exercise price of $0.2968 per share. These options expire on 12/19/2035.
According to the vesting terms, 25% of the common stock underlying the option vests on the grant date, with the remaining balance vesting in equal monthly installments over the following 36 months of continuous service. After this grant, the reporting person beneficially owns 23,724 derivative securities, held directly.
Azitra, Inc. reported an equity award to its President, CEO and director, Francisco D. Salva. On 12/19/2025, he received a stock option to buy 59,309 shares of Azitra common stock at an exercise price of $0.2968 per share. The option expires on 12/19/2035.
According to the vesting terms, 25% of the shares vest on the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months of continuous service. Following this grant, 59,309 derivative securities are beneficially owned directly.
Azitra, Inc. director Barbara Ryan reported receiving a new stock option grant. On 12/19/2025, she was awarded options to purchase 3,003 shares of Azitra common stock at an exercise price of $0.2968 per share. These options are held directly.
According to the vesting terms, 25% of the underlying shares vest on the grant date, referred to as the Vesting Commencement Date. The remaining shares vest in equal monthly installments over the following 36 months of continuous service. The options have an expiration date of 12/19/2035.
Azitra, Inc. reported an insider equity award for its Chief Financial Officer on a Form 4. On 12/19/2025, the CFO received stock options to buy 15,015 shares of Azitra common stock at an exercise price of $0.2968 per share. These options are exercisable through 12/19/2035.
According to the vesting terms, 25% of the shares underlying the option vest on the grant date, and the remaining balance vests in equal monthly installments over the next 36 months of continuous service. Following this transaction, the reporting person beneficially owns 15,015 derivative securities directly.
Azitra, Inc. director John R. Schroer reported receiving a stock option grant. On 12/19/2025, he was granted options to purchase 3,003 shares of Azitra common stock at an exercise price of $0.2968 per share, with no purchase price for the option itself.
According to the vesting terms, 25% of the shares underlying the option vest on the grant date, designated as the vesting commencement date. The remaining shares vest in equal monthly installments over the next 36 months of continuous service. The options are scheduled to expire on 12/19/2035, and following this grant Schroer beneficially owns 3,003 derivative securities directly.
Azitra, Inc. shareholder Alumni Capital LP and related entities filed an amended ownership report showing beneficial ownership of 1,132,622 Azitra common shares, or 9.99% of the class. The shares include stock already owned plus shares that may be acquired under an April 2025 purchase agreement and several series of warrants.
The filing explains 9.99% and 4.99% beneficial ownership limits embedded in the purchase agreement and warrants, which cap how many shares Alumni Capital and its affiliates can hold at any time. Alumni Capital currently owns 535,759 shares and has the right to acquire additional shares through commitment warrants, with potential increases if it sells some of its existing position.
The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Azitra.
Azitra, Inc. reports that NYSE American has accepted its plan to regain compliance with the exchange’s minimum stockholders’ equity listing standard and granted a plan period through April 1, 2027.
Azitra previously received a notice on October 1, 2025 that it was not in compliance with Section 1003(a)(ii), which requires stockholders’ equity of
Azitra, Inc. is registering up to 51,812,293 shares of common stock for resale by Alumni Capital and other selling stockholders under a November 2025 private placement and an existing equity line of credit (ELOC). The shares include stock already issued plus shares underlying pre-funded warrants, common stock purchase warrants, placement agent warrants and ELOC warrants. Azitra will not receive proceeds from stockholder resales but may receive up to about
FAQ
What is the current stock price of Azitra (AZTR)?
What is the market cap of Azitra (AZTR)?
